Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + paclitaxel + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a multi-agent combination regimen consisting of five drugs—cyclophosphamide, doxorubicin, paclitaxel, pertuzumab, and trastuzumab—used primarily in the treatment of HER2-positive breast cancer. Cyclophosphamide is an alkylating agent that interferes with DNA replication. Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. Paclitaxel is a taxane that stabilizes microtubules and prevents cell division. Pertuzumab and trastuzumab are monoclonal antibodies targeting different domains of the human epidermal growth factor receptor 2 (HER2), blocking its signaling pathways to inhibit tumor growth. This combination leverages cytotoxic chemotherapy with dual HER2 blockade for improved efficacy in early-stage, locally advanced, or metastatic HER2-positive breast cancer[1][2][3][5][7].
- Brand names
- AdriamycinCytoxanTaxolHerceptinPerjeta
- Other names
- AC followed by THPAC/Taxol-Trastuzumab-Pertuzumab regimenACTHP regimen
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + paclitaxel + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + paclitaxel + pertuzumab + trastuzumab.